Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

1708997- 43-6Upadacitinib Des Tosyl Impurity

● Auf Lager

Katalog-Nr.::	VE0027851
CAS-Nr.::	1708997- 43-6
Summenformel::	C14H17N5
Molare Masse::	255.32 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 1708997- 43-6

Parent drug

Upadacitinib

IUPAC-Name

8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo[1,2-a] pyrrolo[2,3-e] pyrazine

Pharmacopeial Synonyms

N/A

Synonyme

N/A

SMILES

CC[C@H]1[C@@H](C2=CN=C3C=NC(NC=C4)=C4N32)CNC1

InChI

InChI=1S/C14H17N5/c1-2-9-5-15-6-10(9)12-7-17-13-8-18-14-11(19(12)13)3-4-16-14/h3-4,7-10,15-16H,2,5-6H2,1H3/t9-,10+/m1/s1

Beschreibung

Upadacitinib Des Tosyl Impurity (CAS 1708997-43-6) is a structurally related process impurity arising from incomplete tosyl protection removal during upadacitinib synthesis. It is characterized by mass spectrometry and retention behavior consistent with des-tosylated analogs and commonly monitored by validated HPLC and LC-MS methods to support impurity profiling and batch release. Typical control measures include reaction optimization, purification by crystallization or preparative chromatography, and specification limits defined per ICH Q3A guidelines. Stability studies assess its formation under thermal and hydrolytic stress, while accurate quantitation at low ppm levels is critical to ensure API purity and regulatory compliance.